Stapokibart - KeyMed Biosciences/Shanghai JMT-BIO Technology
Alternative Names: Anti-IL-4Rα recombinant fully humanized antibody - KeyMed Biosciences; CM-310; CM310 Recombinant humanized monoclonal antibody injection; IL-4Rα(mAb) - KeyMed Biosciences; Kangyueda; Scipibazumab - KeyMed Biosciences; StapokibatrtLatest Information Update: 13 May 2025
At a glance
- Originator KeyMed Biosciences
- Developer KeyMed Biosciences; Shanghai JMT-BIO Technology
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 4 receptor alpha subunit antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Allergic rhinitis; Atopic dermatitis; Rhinosinusitis
- Phase III Prurigo nodularis
- Phase II/III Asthma; Chronic obstructive pulmonary disease